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Abstract
INTRODUCTION: WNT5A belongs to the Wnt family of secreted signaling molecules. Using transcriptional pro-
filing, we previously identified WNT5A as target of the antiapoptotic transcription factor CUX1 and demonstrated
high expression levels in pancreatic cancer. However, the impact of WNT5A on drug resistance and the signaling
pathways employed by WNT5A remain to be elucidated. OBJECTIVES: This project aims to decipher the impact of
WNT5A on resistance to apoptosis and the signaling pathways employed byWNT5A in pancreatic cancer.METHODS:
The impact of WNT5A and its downstream effectors on tumor growth and drug resistance was studied in vitro
and in xenograft models in vivo. Tissue microarrays of pancreatic cancer specimens were employed for immuno-
histochemical studies. RESULTS: Knockdown of WNT5A results in a significant increase in drug-induced apoptosis.
In contrast, overexpression of WNT5A or addition of recombinant WNT5A mediates resistance to apoptosis in vitro.
In our attempt to identify downstream effectors of WNT5A, we identified the transcription factor nuclear factor of
activated T cells c2 (NFATc2) as transcriptional target of WNT5A signaling. NFATc2 confers a strong antiapoptotic
phenotype mediating at least in part the effects of WNT5A on drug resistance and tumor cell survival. In vivo, WNT5A
expression leads to resistance to gemcitabine-induced apoptosis in a xenograft model, which is paralleled by up-
regulation of NFATc2. Both WNT5A and NFATc2 proteins are highly expressed in human pancreatic cancer tissues
and their expression levels correlated significantly. CONCLUSION: We identified the WNT5A-NFATc2 axis as impor-
tant mediator of drug resistance in pancreatic cancer.
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Introduction
The Wnt family of proteins are secreted cysteine-rich glycoproteins
comprising 19 highly conserved members [1] that have been shown to
play a pivotal role in embryogenesis, development, and tissue homeo-
stasis. Wnt proteins lack transmembrane domains, are posttranslation-
ally modified by glycosylation [2], and are known to bind to the
Frizzled family of transmembrane receptors [3]. Various Wnt genes
are differentially expressed during embryogenesis and among various
tissues, including stem cell compartments of several organs [4].
In addition to their crucial role in embryogenesis and development,
several Wnt ligands have been linked to carcinogenesis and tumor pro-
gression: High levels of certain Wnt family members such as WNT1,
WNT3A, and WNT7A are capable of transforming various cell types
into tumor cells. Other Wnt ligands such as WNT4, WNT5A, and
WNT6, however, fail to induce cellular transformation [5].
The role ofWNT5A in tumorigenesis remains ambiguous. In hema-
topoietic cells as well as breast and renal cancers, WNT5A has been
shown to inhibit tumor cell proliferation [6–8] and was associated with
a good prognosis [9]. However, accumulating data in other tumor types
indicate that increased WNT5A expression may actually promote cancer
progression. For example, WNT5A has been demonstrated as potent
enhancer of cell motility and invasiveness in melanomas [10] and is highly
expressed in various cancers of the lung, stomach, and prostate [11–13].
The downstream signaling events induced by WNT5A also re-
main controversial and may be cell type–dependent [14]. Most
Wnt members signal through Frizzled receptors and activate the
dishevelled gene, resulting in the inhibition of glycogen synthase
kinase-3 beta (GSK-3β) activity and the subsequent stabilization of
its target β-catenin, which results in altered gene transcription. In
contrast to this “canonical” pathway, other Wnt members may also
signal through “noncanonical” pathways such as the Wnt-calcium
pathway involving activation of phospholipase C, protein kinase C
(PKC), and calmodulin-dependent protein kinase II (CaMKII) or
the planar cell polarity pathway involving cytoskeletal reorganization
and activation of Rac/Rho GTPases [14–17].
In many cell types, WNT5A has been described to signal through
noncanonical Wnt signaling pathways, although it also has the poten-
tial to activate the canonical Wnt signaling pathway depending on the
receptor context [14,16,17]. In addition to signaling through the Frizzled
receptors, WNT5A may activate receptor tyrosine kinases such as Ror2
and Ryk, which are able to inhibit canonical Wnt signaling [18].
Interestingly, in several cell types such as osteoblasts, mammary
epithelial cells, and endothelial cells, a link between WNT5A and
the nuclear factor of activated T cells (NFAT) transcription factor fam-
ily has been proposed [9,19,20]. The NFAT family comprises four
members of calcium/calcineurin-regulated proteins particularly recog-
nized for their central roles in gene regulation during T-lymphocyte
activation [21]. However, a multitude of studies have demonstrated
that NFAT proteins are also expressed in cells outside the immune
system, and emerging evidence indicates a key role for two NFAT
members, NFATc1 and NFATc2, during carcinogenesis by regulating
crucial aspects of neoplastic transformation and tumor progression [21].
Both isoforms are frequently overexpressed in epithelial malignancies,
which is associated with a highly malignant phenotype [22].
Recently, we identifiedWNT5A as an important downstream effector
of the homeodomain transcription factor CUX1, also known as CUTL1
[16]. We had shown before that CUX1 mediates tumor invasion and
tumor cell survival in solid tumors including pancreatic cancer [23,24].
On the basis of these data, it was the aim of this study to characterize the
role of the CUX1 target WNT5A on tumor cell survival and drug resis-
tance and to decipher the signaling events downstream WNT5A.
Materials and Methods
Material and Cell Lines
ImimPC1 cells were kindly provided by F. X. Real (Centro
Nacional de Investigaciones Oncológicas, Madrid, Spain) [25].
The PaTu-8988t cell line was received from the German Collection
of Cell Lines (DSMZ, Braunschweig, Germany). Both cell lines were
derived from human primary ductal adenocarcinomas (PaTu-8988t)
or liver metastases of pancreatic ductal adenocarcinomas (ImimPC1)
and carry activating K-Ras mutations. Stable PaTu-8988t–NFATc2
cells are a kind gift from V. Ellenrieder (University of Marburg).
Cells were maintained in Dulbecco’s modified Eagle’s medium (Gibco,
Darmstadt, Germany) supplemented with 10% fetal calf serum (Gibco)
and 250 μg/ml gentamicin (PAA, Cölbe, Germany). The amphotropic
packaging cell line LinX was maintained in Dulbecco’s modified Eagle’s
medium, 10% fetal calf serum, gentamicin, and 100 μg/ml hygromycinB
(Roth, Karlsruhe, Germany). All cells were cultured in a humidified
atmosphere containing 5% CO2 at 37°C. Gemcitabine was obtained
from Lilly (Bad Homburg, Germany) and tumor necrosis factor–related
apoptosis-inducing ligand (TRAIL) and rWnt5A from R&D Systems
(Wiesbaden-Nordenstadt, Germany). Reagents were used at the follow-
ing working concentrations: TRAIL, 15 ng/ml; gemcitabine, 80 μg/ml;
rWNT5A, 500 ng/ml; doxycycline (Sigma-Aldrich, Taufkirchen bei
München, Germany), 4 μg/ml; puromycin (Sigma), 1.25 μg/ml; G418
(PAA), 100 μg/ml.
Plasmids and Small Interfering RNA
The open reading frame (ORF) of hWNT5A was amplified by po-
lymerase chain reaction (PCR) from the human cDNA clone
MGC:71588 IMAGE:30346200 and cloned into the Tet-repressible
expression vector pBig2r [26], which was a kind gift of J. R. Hall, using
the KpnI and SpeI restriction sites. The pBig2r-WNT5A and empty
pBig2r vectors were transfected into PaTu-8988t cells. For generation
of stable clones, cells were cultured in the presence of 400 μg/ml hygro-
mycin B. Stable expression of WNT5A was confirmed after incubation
with doxycycline (4 μg/ml for 24 hours) through immunoblot analysis.
Stable ImimPC1 cells were generated using a retroviral system. For
retroviral expression, WNT5A was amplified and cloned into pENTR
vector using pENTR/D-TOPO Cloning Kit (Invitrogen, Darmdstadt,
Germany) and recombined into a Gateway competent pQCXIP vector
(kind gift from T. Stiewe, University of Marburg). The luciferase re-
porter constructs pNFAT and cisNFAT were kindly provided by V.
Ellenrieder (University of Marburg). The pGL3-Enhancer as control
was purchased from Promega (Mannheim, Germany). Small interfering
RNA (siRNA) purchased from Ambion (Darmstadt, Germany) against
WNT5A or NFATc2 was transfected at a final concentration of 10 nM
using RNAiMAX (Invitrogen) according to the manufacturer’s protocol.
All results could be verified by two independent silencing sequences.
Retroviral Infection
To produce retroviruses, we transfected LinX packaging cells with
5 μg of retroviral vectors; 48 and 72 hours after transfection, the
retrovirus-containing supernatant was harvested, filtered, and sup-
plemented with 8 μg/ml polybrene (Sigma). Target cells were trans-
duced by spin infection at 1500 rpm, 37°C for 1 hour and selected
with puromycin and G418.
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Luciferase Reporter Assays
ImimPC1 and PaTu-8988t cells seeded in 24-well plates were
transfected with luciferase plasmids using Transfast transfection re-
agent (Promega) according to the manufacturer’s instructions and
harvested 24 hours after transfection. Luciferase assays were per-
formed using the Luciferase-Reporter Assay System (Promega), as de-
scribed previously [23].
RNA Isolation, cDNA Synthesis, and Real-Time PCR
RNA isolation and first-strand cDNA synthesis were performed using
peqGold RNAPure (Peqlab, Erlangen, Germany) and the Omniscript
RT-Kit (Qiagen, Hilden, Germany) according to the manufacturers’
instructions. Quantitative real-time PCR analysis was performed using
the ABI PRISM 7500 Sequence Detector System and the SYBR Green
PCR Master Mix Kit (Applied Biosystems, Darmstadt, Germany). The
ribosomal protein RPLPO (NM_001002) was used as internal standard.
Immunoblot Analysis
Cells were lysed in RIPA buffer supplemented with complete
protease inhibitor cocktail (Roche, Mannheim, Germany). Nuclear and
cytoplasmic fractions were performed using the ProteoJET Cytoplasmic
and Nuclear Protein Extraction Kit (Fermentas, St. Leon-Rot, Germany).
Thirty micrograms of lysates was separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and transferred to Immobilon-P
polyvinylidene fluoride membranes (Millipore, Darmstadt, Germany).
Immunoblots were probed with primary antibodies against WNT5A
(R&D Systems), NFATc2 (Santa Cruz Biotechnology, Heidelberg,
Germany), poly(ADP-ribose) polymerase (PARP; Cell Signaling
Technology, Frankfurt am Main, Germany), ORC-2 (Santa Cruz
Biotechnology), phospho-β-catenin (Ser-37, Thr-41; Millipore) and β-actin
(Sigma). Peroxidase-conjugated secondary antibodies against mouse
or rabbit were obtained from Amersham (Freiburg, Germany) and goat
from Sigma. Blots were detected byWestern Lightning ECL (PerkinElmer,
Rodgau, Germany).
Apoptosis Assays
Histone-associated DNA fragments were quantified using Cell
Death Detection ELISAPLUS (Roche) according to the manufac-
turer’s instructions. Caspase-3 and -7 activity was measured using
Caspase-Glo 3/7 assay (Promega) according to the manufacturer’s in-
structions. The luminescence is proportional to the amount of cas-
pase activity. PARP cleavage was assessed with a specific antibody
detecting cleaved PARP (Cell Signaling).
Fluorescence-activated Cell Sorting (FACS)
FACS analysis was used to determine DNA fragmentation of propi-
dium iodide–stained nuclei as described before [24,27]. In brief, cells
were stained with propidium iodide after RNase treatment and ana-
lyzed in a FACScan flow cytometer (BD Biosciences, Heidelberg,
Germany). Cell cycle was analyzed using the FlowJo software (Tree Star,
Ashland, OR). Apoptosis assays by annexin V staining were performed
according to the manufacturer’s instructions (BD Biosciences).
Immunohistochemistry
For expression analysis of WNT5A and NFATc1, a multiple tissue
array (MTA) that was generated in the Department of Pathology,
Technical University of Dresden according to the guidelines of the
local ethics committee was used. Immunohistochemical analysis was
performed as previously described [24]. In short, paraffin sections
were stained after antigen retrieval (microwave in antigen unmasking
solution; Vector Laboratories, Burlingame, CA) with rabbit polyclonal
anti-WNT5A (1:100; Abcam, Cambridge, United Kingdom) or
NFATc2 (1:200; Abcam). Antibody binding was visualized using a bio-
tinylated secondary antibody, avidin-conjugated peroxidase (ABC
method; Vector Laboratories), and 3,3′-diaminobenzidine tetrachloride
as a substrate and hematoxylin as counterstain. TheMTAs were analyzed
semiquantitatively as − (negative), + (25–50% positive tumor cells),
++ (50–75% positive tumor cells), +++ (>75% positive tumor cells).
Animals and Xenografts
Athymic female nude mice were purchased from Charles River
(Sulzfeld, Germany). Mice were housed in a climate-controlled SPF
facility. All animal experiments were approved by the local government
authorities and were performed according to the guidelines of the
animal welfare committee.
Nude mice were injected subcutaneously with 1 × 106 ImimPC1
cells dispersed in 0.1 ml of normal saline at each flank. Six mice per
group were injected with cells stably transfected with either WNT5A
or empty vector. When tumors reached a volume of approximately
100 mm3, mice were randomized into two groups and injected twice
a week with gemcitabine [25 ng/g body weight intraperitoneally (i.p.)
dissolved in phosphate-buffered saline (PBS)] or PBS only as control.
Tumor growth was measured using a caliper twice weekly for a total of
20 days.
Statistical Analysis
Statistical analysis of tumor growth was performed with GraphPad
Prism software using two-way analysis of variance. All numerical data
are reported as the means ± SD. Correlation of WNT5A and NFAT
expression on the tissue microarrays was calculated with IBM
SPSS19 (IBM, Ehningen, Germany) using Spearman-Rho analysis.
Results
Knockdown of WNT5A Enhances Drug- and TRAIL-Induced
Apoptosis in Pancreatic Cancer Cell Lines
We first evaluated the effect of WNT5A on basal as well as drug-
and TRAIL-induced apoptosis in pancreatic cancer cell lines. As
apoptosis-inducing drug, we used the nucleoside analog gemcitabine,
which is commonly applied in pancreatic cancer patients. Knock-
down of WNT5A by specific siRNA significantly induced basal as
well as gemcitabine-induced apoptosis rates in PaTu-8988t cells,
as determined by assaying different hallmarks of apoptosis includ-
ing histone-associated DNA fragmentation using a specific ELISA
(Figure 1A) and effector caspase-3/7 activity using a specific assay
that measures cleavage of a luminogenic caspase-3/7 substrate (Fig-
ure 1B), cleavage of PARP (Figure 1C ), and annexin V staining (Fig-
ure 1D). The effects of WNT5A knockdown on apoptosis could be
corroborated in other pancreatic cancer cell lines such as ImimPC1
cells, as determined by PARP cleavage (Figure W1A). In addition, all
assays could be confirmed by the use of two independent WNT5A-
specific siRNA oligonucleotides, which both led to a marked knock-
down of WNT5A protein expression and had been validated previously
(Figure W1, B and C) [16].
Chemotherapeutic drugs characteristically trigger apoptosis through
induction of DNA damage and activation of the intrinsic apoptosis
pathway. By comparison, TRAIL is known to induce the death re-
ceptor pathway of apoptosis through binding to its cognate surface
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receptors (extrinsic pathway). Similar to gemcitabine-induced apop-
tosis, knockdown of WNT5A sensitized to apoptosis induced by
TRAIL, as determined by FACS sub-G1 analysis (Figure W2, A and
B), PARP cleavage (Figures 1C and W1A), and caspase-3/7 activity
assays (Figure W3) in PaTu-8988t and ImimPC1 cells. These results
indicate that down-regulation of WNT5A by siRNA effectively en-
hances the sensitivity of pancreatic cancer cell lines to apoptosis in-
duced by different stimuli that trigger apoptosis through extrinsic or
intrinsic pathways.
Expression of WNT5A Protects from Drug-Induced Apoptosis
To exclude the possibility that only knockdown of endogenous
WNT5A affects apoptosis, we examined whether overexpression of
WNT5A protects from drug-induced apoptosis. For that purpose,
we generated PaTu-8988t cells stably expressing WNT5A in a Tet-
repressible manner: In these cells, addition of doxycycline decreased
stably overexpressed WNT5A to normal levels (Figure W4A). Using
this repressible cell system, we could show that overexpressed WNT5A
significantly decreased apoptosis induced by incubation with gemcita-
bine for 24 or 48 hours (Figure 2A). Similar to these findings, addition
of exogenous recombinant WNT5A led also to a significant protection
from gemcitabine-induced apoptosis (Figure 2B) that could be corrob-
orated in both PaTu-8988t and ImimPC1 by PARP cleavage assays
(Figure W4, B and C ). These data indicate that WNT5A is able to
rescue from drug-induced apoptosis. A similar trend was observed in
TRAIL-induced apoptosis, which, however, did not reach statistical
significance (Figure W4D).
WNT5A Rescues from Drug-Induced Apoptosis In Vivo
To corroborate our in vitro findings implicating WNT5A as regu-
lator of resistance to apoptosis in vivo, we used xenograft experiments in
nude mice. Because ImimPC1 cells are known to form subcutaneous
xenograft tumors, we generated ImimPC1 cell lines stably overexpress-
ing WNT5A or empty control vectors and injected them into nude
mice. After tumors reached a volume of approximately 100 mm3, i.p.
treatment with gemcitabine or PBS was started. WNT5A overexpres-
sion significantly abolished the growth inhibitory effect of gemcitabine
treatment compared to control xenografts (Figure 2C). In contrast, in
the absence of gemcitabine, tumor growth was not significantly acceler-
ated byWNT5A (FigureW4E). In addition, the impact ofWNT5A on
gemcitabine-induced growth inhibition was paralleled by a strong up-
regulation of antiapoptotic proteins such as BCL2, supporting the effect
of WNT5A on resistance to drug-induced apoptosis (Figure 2D).
WNT5A Regulates NFATc2 mRNA
WNT5A acts as secreted ligand in autocrine or paracrine manner.
The intracellular signaling events following WNT5A stimulation have
been controversially discussed and appear to be cell type–dependent.
Figure 1. Knockdown of WNT5A induces apoptosis. (A) PaTu-8988t cells were transiently transfected with WNT5A siRNA (siWNT5A) or
control siRNA (siC), and apoptosis was induced with gemcitabine for 24 hours. Apoptosis was determined by quantification of histone-
bound DNA fragmentation using a specific ELISA. (B) Apoptosis after knockdown of WNT5A by siRNA and apoptosis induced by gemci-
tabine, as assessed by a caspase-3/7 activation assay. Percentage of apoptotic cells is shown as mean of three independent experiments
± SD. *P< .05 as compared with control cells; **P< .05 as compared with drug-treated control cells. (C) PARP cleavage after WNT5A knock-
down by siRNA and gemcitabine (48 hours)– or TRAIL (12 hours)–induced apoptosis was assayed by a PARP-specific antibody detecting the
cleaved PARP (lower band). To control for equal loading, the blots were reprobed with β-actin antibody. (D) Annexin V FACS analysis ±
WNT5A siRNA (siWNT5A) or control siRNA (siC) ± gemcitabine (48 hours). Apoptosis was determined by Annexin V (AnV) and propidium
iodide (PI) staining and subsequent FACS analysis. Percentage of early apoptotic cells (PI−/AnV+) and late apoptotic/necrotic cells (PI+/AnV+)
is shown as percentage of events. Data are representative for three independent experiments.
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Therefore, we aimed to elucidate the intracellular signaling pathways
activated by WNT5A in pancreatic cancer. Previous reports suggested
an interaction between WNT5A and NFAT signaling in several cell
types such as osteoblasts, mammary epithelial cells, and endothelial cells
[9,19,20]. Moreover, we could previously demonstrate high expression
levels of NFATc2 in pancreatic cancer tissues [28]. In our search for
downstream effectors of WNT5A in pancreatic cancer, we therefore
investigated a possible link between WNT5A and NFATc2. After
knockdown of WNT5A by siRNA in PaTu-8988t cells, we indeed ob-
served a significant decrease of NFATc2 mRNA, as measured by quan-
titative real-time PCR (Figure 3A). These results could be confirmed on
promoter level by luciferase assays: Knockdown of WNT5A leads to a
marked decrease in NFATc2 promoter activity (Figure 3B). In contrast,
incubation with recombinant WNT5A increased NFATc2 mRNA
peaking after a 4-hour incubation (Figure 3C). Likewise, addition of
WNT5A increased NFATc2 promoter activity in PaTu-8988t cells
(Figure 3D). These results could also be confirmed in ImimPC1 cells
(Figure W5).
WNT5A Regulates NFATc2 on Protein Level
To verify the regulation of NFATc2 by WNT5A on protein level,
we suppressed WNT5A by siRNA and analyzed NFATc2 protein
expression by Western blot. WNT5A knockdown led to a marked re-
duction of NFATc2 protein both in PaTu-8988t cells (Figure 4A) and
ImimPC1 cells (Figure W6A). Because NFATc2 is known to shuttle
from the cytoplasm to the nucleus following dephosphorylation by
calcineurin, we generated nuclear extracts after knockdown ofWNT5A
and tested for potential effects of WNT5A on NFATc2 localization.
Figure 2.WNT5A rescues from drug-induced apoptosis. (A) PaTu-8988t cells with Tet-repressible WNT5A expression were incubated in
the presence (low WNT5A) or absence (high WNT5A) of doxycycline (dox) and exposed to gemcitabine for 24 or 48 hours. Apoptosis
was determined by quantification of histone-bound DNA fragmentation using a specific ELISA. *P < .05 as compared with +dox cells
treated with gemcitabine for 24 hours; **P < .05 as compared with +dox cells treated with gemcitabine for 48 hours. (B) PaTu-8988t
cells were incubated with recombinant WNT5A and exposed to gemcitabine for 24 or 48 hours. Apoptosis was determined by quan-
tification of histone-bound DNA fragmentation using a specific ELISA. *P < .05 as compared with control cells treated with gemcitabine
for 24 hours; **P < .05 as compared with control cells treated with gemcitabine for 48 hours. Data are representative for three indepen-
dent experiments. (C) Tumor growth of subcutaneous ImimPC1 cells stably overexpressingWNT5A or empty control vectors (n=6 each).
After the tumors had reached a volume of approximately 100 mm3, treatment with gemcitabine i.p. or PBS i.p. was started and tumor
volume was determined for 20 days. *P < .05 as compared with control xenografts. (D) Expression of WNT5A and BCL2 in protein
lysates of gemcitabine-treatedWNT5A-overexpressing or mock-transfected ImimPC1 xenografts, for which material for protein lysates
was available.
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Figure 3. WNT5A induces NFATc2 mRNA. (A) PaTu-8988t cells were transiently transfected with WNT5A siRNA (siWNT5A) or control
siRNA (siC). NFATc2 mRNA was determined by quantitative real-time PCR normalized to RPLPO mRNA. (B) PaTu-8988t cells ± WNT5A
siRNA or control siRNA were cotransfected with a luciferase plasmid containing an NFATc2 promoter fragment. Promoter activation
was measured by luciferase assay. (C) NFATc2 mRNA was determined by quantitative real-time PCR after incubation with rhWNT5A for
the indicated time points. (D) NFATc2 promoter activity was determined by luciferase assay after transfection with the NFATc2 promoter
luciferase plasmid and incubation with rhWNTA for 24 hours. *P< .05 as compared with untreated control cells. Data are representative
for three independent experiments.
Figure 4.WNT5A induces NFATc2 protein. (A) PaTu-8988t cells were transfected with WNT5A siRNA (siWNT5A) or control siRNA (siC),
and NFATc2 protein was determined by Western blot. (B) NFATc2 protein was measured in nuclear and cytoplasmic preparations from
PaTu-8988t cells ± WNT5A siRNA or control siRNA. ORC2 was used as a loading control in the nuclear fractions. (C) PaTu-8988t cells
with Tet-repressible WNT5A expression were incubated ± doxycycline for 24 hours. NFATc2 protein levels were detected by Western
blot. (D) rhWNT5A was added to PaTu-8988t cells for various time points and NFATc2 protein levels were analyzed by Western blot.
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At baseline, NFATc2 protein levels were detected in the nucleus and
cytoplasm, both of which were markedly reduced after WNT5A
knockdown. Therefore, we could rule out a relevant WNT5A-
dependent nuclear-cytoplasmic shuttling (Figure 4B).
To confirm that NFATc2 protein is upregulated after WNT5A over-
expression, we used PaTu-8988t cells stably expressing Tet-repressible
WNT5A. ElevatedWNT5A levels in the absence of doxycycline clearly
correlated with increased NFATc2 protein levels (Figure 4C). Likewise,
stable overexpression of WNT5A in ImimPC1 cells resulted in in-
creased NFATc2 levels (Figure W6B). Moreover, exogenously added
recombinant WNT5A led to an increase in NFATc2 protein within
12 hours in both PaTu-8988t cells (Figure 4D) and ImimPC1 cells
(Figure W6C).
In analogy to these in vitro findings, expression levels of theWNT5A
target NFATc2 in the WNT5A overexpressing xenograft tumors
described above were markedly increased (Figure W6C ), confirming
that NFATc2 is upregulated by WNT5A in vivo.
WNT5A Regulates NFATc2 through
β-Catenin–Dependent Mechanisms
Previously, we showed that WNT5A signaling leading to enhanced
migration and invasion in pancreatic cancer cell lines involves β-catenin–
dependent canonical signaling mechanisms [16]. Furthermore, we
would not find evidence of noncanonical, calcium-dependent mech-
anisms or alterations in the cell polarity pathways in pancreatic cancer
cells, as suggested before by reports in other cell systems [16]. On the
Figure 5. WNT5A regulates NFATc2 through β-catenin–dependent signaling pathways. (A) PaTu-8988t cells were incubated with
rhWNT5A for the indicated time points, and transcriptionally inactive β-catenin (phosphorylated Ser-37, Thr-41) was determined using a
phospho-specific antibody. (B) PaTu-8988t cells were transiently transfected with siRNA against β-catenin (si-β-catenin) or nonsilencing con-
trol (siControl), and NFATc2 protein levels were detected by Western blot after separation of nuclear (N) or cytoplasmic (C) proteins.
Figure 6. WNT5A induces transcriptional activation of NFATc2. (A) PaTu-8988t cells were transiently transfected with WNT5A siRNA
(siWNT5A) or control siRNA (siC) and cotransfected with a cisNFAT luciferase plasmid (cisNFAT-Luc) containing an NFAT DNA binding
motif. NFAT transcriptional activation was measured by luciferase assay. (B) PaTu-8988t cells with Tet-repressible WNT5A expression
were transfected with cisNFAT-Luc ± doxycycline for 24 hours. (C) rhWNT5A was added to PaTu-8988t cells after transfection with
cisNFAT-Luc. *P < .05 as compared with untreated control cells. Data are representative for three independent experiments.
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basis of these data, we aimed to investigate whether the regulation of
NFATc2 by WNT5A involves β-catenin–dependent signaling. Both
pancreatic cancer cell lines, PaTu-8988t and ImimPC1, expressed re-
ceptors for canonical Wnt signaling such as LRP5 and various Frizzled
receptors but did not or only weakly express the noncanonical receptors
Ror2 or Ryk (Figure W7). Recombinant WNT5A led to a marked
decrease in phosphorylated β-catenin (Figure 5A), which indicates its
increased activity and nuclear translocation, as shown previously [16].
In addition, WNT5A enhanced β-catenin–dependent canonical tran-
scriptional activity, as assayed by measuring TOP/FOPFlash luciferase
signals (FigureW8A). Furthermore, knockdown of β-catenin by siRNA
led to a marked decrease in both nuclear and cytoplasmic NFATc2 pro-
tein levels, indicating a β-catenin–dependent regulation of NFATc2
(Figure 5B).
WNT5A Regulates NFATc2 Transcriptional Activity
After having demonstrated that WNT5A induces NFATc2 on
promoter, mRNA, and protein levels, we aimed to confirm that
Figure 7. (A, B) NFATc2 knockdown stimulates drug-induced apoptosis. PaTu-8988t cells were transiently transfected with NFATc2
siRNA (siNFAT) or control siRNA (siC), and apoptosis was induced with gemcitabine for 48 hours. Apoptosis was determined by quantifi-
cation of histone-bound DNA fragmentation by specific ELISA (A) and PARP cleavage (B). (C, D) NFATc2 mediates resistance to drug-
induced apoptosis. PaTu-8988t cells stably overexpressing NFATc2 and mock-transfected control cells were incubated with gemcitabine
for 48 hours, and apoptosis was assessed by ELISA (C) and PARP cleavage (D). Data are representative of three independent experiments
and presented as means ± SD. *P < .05 as compared with control cells + gemcitabine.
Figure 8. NFATc2 knockdown decreases WNT5A-mediated protection from apoptosis. ImimPC1 cells stably overexpressing WNT5A or
empty control vector were transiently transfected with NFATc2 siRNA (siNFAT) or control siRNA (siC), and apoptosis was induced by
gemcitabine. Apoptosis was determined by quantification of histone-bound DNA fragmentation by ELISA. *P < .05 as compared with
control cells, as indicated. Data are representative for three independent experiments.
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WNT5A stimulation also translates into increased NFAT-dependent
transcriptional activity. For that purpose, we used a luciferase-coupled
NFAT-responsive promoter fragment, cisNFAT-Luc. After WNT5A
knockdown, NFAT transcriptional activity was significantly reduced
in both PaTu-8988t (Figure 6A) and ImimPC1 cells (Figure W8B).
Conversely, WNT5A overexpression (Figure 6B) and incubation with
recombinant WNT5A led to an increase in NFAT transcriptional
activity (Figures 6C and W8C).
NFATc2 Rescues from Drug-Induced Apoptosis
On the basis of these data, we were interested whether NFATc2
is able to mediate the antiapoptotic effects of WNT5A. For that
purpose, we examined drug-induced apoptosis after knockdown
and overexpression of NFATc2.
In analogy to the effects described for WNT5A, knockdown of
NFATc2 resulted in a significant increase of gemcitabine-induced
apoptosis, as assessed by histone-associated DNA fragmentation
(Figure 7A). This was paralleled by a significant increase in PARP
cleavage after NFATc2 knockdown (Figure 7B). Similar results were
observed in ImimPC1 cells (Figure W9A) and with two independent
NFATc2 siRNA silencing sequences (Figure W9B). In analogy to the
previous data with WNT5A, stable overexpression of NFATc2 in
PaTu-8988t cells led to a significant resistance to apoptosis induced
by gemcitabine, as measured by DNA fragmentation (Figure 7C )
and PARP cleavage (Figure 7D).
Interestingly, addition of gemcitabine led to a marked decrease
in endogenous NFATc2 protein levels in PaTu-8988t cells (Figure 7,
B and D) but not in ImimPC1 cells (Figure W9C ). The molecular
mechanism underlying this phenomenon remains to be elucidated.
In analogy to the findings in gemcitabine-induced apoptosis, NFATc2
also reduced TRAIL-induced apoptosis (Figure W9, C and D).
To assess the importance of NFATc2 as downstream mediator
of WNT5A-induced antiapoptotic effects, we used ImimPC1 cells
stably overexpressing WNT5A and transiently reduced NFATc2 levels
by siRNA (Figure 8). As expected, WNT5A reduced gemcitabine-
induced apoptosis. Knockdown of NFATc2 significantly impaired
but did not completely abolish the protective effect of WNT5A
(Figure 8). These data indicate that NFATc2 mediates a significant
proportion of the antiapoptotic actions of WNT5A in pancreatic
cancer cells. However, additional effector pathways downstream
WNT5A might be involved as well.
WNT5A and NFATc2 Are Coexpressed in
Pancreatic Cancer Tissues
To assess the protein expression of both WNT5A and NFATc2 in
pancreatic cancer tissues, we used MTAs containing 143 different
pancreatic tissues. Immunohistochemical analysis was performed
for both WNT5A and NFATc2. Expression levels of both proteins
were evaluated independently from each other in a semiquantitative
manner. Both WNT5A and NFATc2 were strongly expressed in
Figure 9. Representative immunohistochemical expression of WNT5A (upper row) and NFATc2 (bottom row) in two adjacent sections
each of three pancreatic cancer tissues demonstrating a significant correlation between WNT5A and NFATc2 expression.
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43% and 39% of the tissues, respectively. Interestingly, WNT5A
and NFATc2 expression correlated significantly with each other (P <
.01; Figure 9).
Discussion
In this study, we could demonstrate that WNT5A plays an im-
portant role in protecting pancreatic cancer cells from apoptosis
induced by TRAIL and the nucleoside analog gemcitabine both
in vitro and in vivo. The pro-survival effect of WNT5A was associated
with transcriptional up-regulation of NFATc2 that also conferred a
strong antiapoptotic phenotype in pancreatic cancer cells.
In the literature, the role of WNT5A in tumors has been a matter
of controversy and the data on its effect on tumor cell survival and
metastasis remain conflicting.
On the one hand, WNT5A has been shown to act as tumor sup-
pressor by antagonizing the transforming capacities of other Wnts
[29]. Furthermore, WNT5A inhibits proliferation of leukemic B cells,
and WNT5A hemizygous mice have been reported to develop myeloid
leukemias and B cell lymphomas [8]. In humans, epigenetic silencing
of WNT5A confers a poor prognosis in patients with acute myeloid
leukemia [30]. In line with these findings in hematological malig-
nancies, WNT5A has been shown to inhibit proliferation and in-
vasiveness of colorectal and thyroid cancer cells [31,32], supporting
the notion that WNT5A might act as a tumor suppressor.
In other cancer entities, however, increased WNT5A expression
is associated with tumor progression and worsened prognosis: In
melanoma, WNT5A expression was an independent risk factor
for reduced survival [33]. Likewise, WNT5A was correlated with
aggressiveness of gastric [34] and ovarian cancers [35].
These conflicting data suggest that the effect of WNT5A on cancer
progression is cell type–dependent. To date, the molecular basis under-
lying these cell type–specific functions of WNT5A remains elusive.
Previously, we identified WNT5A as transcriptional target of the
homeodomain transcription factor CUX1 and described WNT5A
as important mediator of CUX1-induced tumor cell motility and
invasion [16,23]. The effect of WNT5A on tumor cell motility and
metastasis was confirmed by other reports in various tumor types such
as melanoma [10] and gastric cancer cells [34].
In analogy to our recent findings implicating CUX1 as major regu-
lator of drug resistance in vitro and in vivo [24], we now present evi-
dence implicating WNT5A as important effector pathway within the
CUX1-dependent transcriptional network mediating pancreatic cancer
cell survival. This is in line with several reports indicating a possible
role of WNT5A in regulating cell survival and resistance to apoptosis:
Vuga et al. recently showed that WNT5A increased resistance to H2O2-
induced apoptosis in isolated fibroblasts from patients with fibrotic
interstitial lung disease [36]. Furthermore, WNT5A inhibited serum
starvation-induced apoptosis in HEK293 cells [37] and in osteoblasts
[38]. These data, however, are contrasted by other reports showing
opposing results: Liang et al. proposed that loss of WNT5A inhibits
apoptosis of CD4+CD8+ thymocytes, whereas exogenous WNT5A
increases apoptosis of fetal thymocytes in culture [39].
The diversity of WNT5A effects observed in different cell systems
suggests that different receptor equipment and/or the recruitment of
different intracellular cascades might modulate WNT5A action in a
given cell type. Traditionally, WNT5A has been proposed to signal
through β-catenin–independent, noncanonical cascades including the
calcium-dependent or planar cell polarity pathway [3]. Interestingly,
we previously failed to detect alterations in calcium-dependent signal-
ing such as CaMKII or PKC activation, nor did we observe planar cell
polarity–related signals such as c-Jun N-terminal kinase (JNK) activa-
tion following WNT5A stimulation in pancreatic cancer cells [16].
However, we found an increase in canonical signaling including
GSK-3β phosphorylation and β-catenin translocation after WNT5A
activation [16]. These findings are in line with other reports that
WNT5A might indeed be able to stimulate β-catenin transcriptional
activation, depending on a distinct receptor context that requires the
presence of the Wnt receptors Frizzled-4 and low-density lipoprotein
receptor-related protein 5 (LRP-5) and the absence of the recently
identified Wnt receptor ROR2 [3,17].
The activation levels of β-catenin–dependent transcription following
WNT5A stimulation in pancreatic cancer cells is generally moderate,
though significant [16]. Therefore, we aimed to search for additional
downstream effectors that might be able to mediate the profound ac-
tion of WNT5A on tumor cell survival and resistance to drug-induced
apoptosis in pancreatic cancer. One of the potential candidates in this
context is the transcriptional regulator NFAT. The NFAT family of
transcription factors comprises a group of four proteins that play a
critical role in the function of many vertebrate tissues [21]. Besides
their well-documented role in T cell activation, NFAT proteins are
being increasingly recognized for their implications in tumorigenesis,
in particular NFATc1 and NFATc2 [40]. Both NFATc1 and NFATc2
have been described to be highly expressed in pancreatic cancer [28].
NFATc1 has been shown to activate several drivers of tumorigenesis in-
cluding c-myc and cyclin D1 in pancreatic cancer [31]. NFATc2 has also
been associated with tumor progression, e.g., by promoting breast cancer
invasion [41]. However, its role in cancer is still controversial and growth
inhibitory and proapoptotic actions have also been reported [42].
Several reports in the literature have suggested a link between
WNT5A and NFAT signaling: In Xenopus, a regulation of NFAT by
noncanonical Wnt signaling has been described [43]. In mammalian
cells including endothelial cells [20], osteoblasts [20], and chondrocytes
[44], WNT5A has also been associated with increased transcriptional
activation of NFAT. In Bcr-Abl–positive leukemias, Gregory et al.
recently identified NFAT as downstream target of WNT5A in an
RNA interference–based synthetic lethal screen [45]. To our knowl-
edge, our report describing NFAT as downstream target of WNT5A
is the first evidence of this link in solid tumors.
Likewise, the role of NFAT signaling in apoptosis has been dis-
cussed controversially and appears also to be strictly dependent on
the cell type and on the NFAT family member: In T cells, NFATc2
induces apoptosis by activation of CD95L transcription [46]. Likewise,
Alvarez et al. reported that tumor necrosis factor–α causes cell death in
neuronal cells through activation of NFAT signaling [47]. In contrast,
NFATc4 was also shown to protect from apoptosis in cortical neurons
[48]. In renal tubular cells, NFATc4 was induced by carboplatin lead-
ing to increased apoptosis, which is assumed to mediate carboplatin-
induced renal toxicity [49]. In fibroblasts, NFATc2 induced apoptosis,
whereas NFATc1 induced transformation [42]. NFATc1 was also
shown to protect chronic myeloid leukemia (CML) cells from imatinib-
induced cell death [45]. To our knowledge, this is the first report
describing an antiapoptotic effect of NFATc2 in tumors.
Interestingly, some of the reports describing NFAT activation fol-
lowing WNT5A stimulation in other cell types showed a calcium
dependency of NFAT activation, which is in line with the known
calcium-dependent NFAT activation pathway through the phosphatase
calcineurin. As described above, we previously had failed to detect
differences in CaMKII or PKC activation following WNT5A. We
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now performed additional experiments to examine involvement of
calcium-dependent signaling events in pancreatic cancer cells down-
streamWNT5A but again were unable to detect changes in intracellular
calcium concentrations as determined by FURA-2 and G5A-aequorin
measurements or activation of calcineurin activity assays following
WNT5A stimulation, despite of the substantial activation of NFATc2
signaling (Griesmann et al., unpublished). Instead, we observed
that NFATc2 is significantly induced in pancreatic cancer through
β-catenin–dependent mechanisms leading to transcriptional up-
regulation involving the NFATc2 promoter. Interestingly, luciferase
assays after cotransfection of lymphoid enhancer-binding factor-1 (LEF1)
expression plasmids did not reveal a significant regulation of the wild-type
NFATc2 promoter fragment by LEF1 (Griesmann et al., unpublished).
Therefore, we cannot rule out that other members or isoforms of the
TCF/LEF transcriptional complex are involved in the β-catenin–dependent
regulation of the NFATc2 promoter.
In summary, our data indicate that the secreted Wnt ligandWNT5A
represents an important survival factor downstream of the transcription
factor CUX1. In turn, WNT5A induces a transcriptional signaling
cascade depending on NFATc2 and thereby mediates resistance to
apoptosis in pancreatic cancer. Further studies are needed to decipher
the apparent controversial effects of WNT5A signaling in the different
tumor entities. It remains to be investigated whether the transcriptional
up-regulation of NFAT, whichmediates at least in part the antiapoptotic
phenotype induced by WNT5A, can be also confirmed in the tumor
entities responding differently to WNT5A. Given the high expression
levels of WNT5A and NFATc2 in pancreatic cancer tissues that we
have described previously [16,28], both appear to be promising can-
didates for therapeutic targeting to overcome the highly drug-resistant
phenotype of pancreatic cancer.
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Figure W1. (A) Knockdown of WNT5A induces apoptosis in ImimPC1 cells, as determined by PARP cleavage. ImimPC1 cells were tran-
siently transfected withWNT5A siRNA (siWNT5A) or control siRNA (siC), and apoptosis was inducedwith TRAIL for 12 hours or gemcitabine
for 48 hours. PARP cleavage was determined by Western blot using a specific antibody detecting uncleaved (upper band) and cleaved
(lower band) PARPs. To control for equal loading, the blots were reprobedwith β-actin antibody. (B)Western blot demonstrating knockdown
of WNT5A protein by two different independent silencing sequences (#1 and #2) in ImimPC1 and PaTu-8988t cells. (C) Quantification of
basal and gemcitabine-induced apoptosis after knockdown of WNT5A using two independent WNT5A siRNA sequences (siWNT5A#1 and
siWNT5A#2) in ImimPC1 cells. Representative quantification of histone-bound DNA fragmentation using a specific ELISA.
Figure W2. Knockdown of WNT5A induces apoptosis, as determined by sub-G1 analysis. (A) PaTu-8988t and (B) ImimPC1 cells were
transiently transfected withWNT5A siRNA (siWNT5A) or control siRNA (siC), and apoptosis was inducedwith TRAIL for 12 hours. Apoptosis
was determined by FACS sub-G1 analysis. Percentage of apoptotic cells is shown as mean of three independent experiments ± SD.
*P < .05 as compared with control cells; **P < .05 as compared with drug-treated control cells.
Figure W3. Knockdown of WNT5A induces apoptosis, as determined by measuring caspase-3/7 activity. (A) PaTu-8988t and (B)
ImimPC1 cells were transiently transfected with WNT5A siRNA (siWNT5A) or control siRNA (siC), and apoptosis was induced with TRAIL
for 12 hours. Effector caspase-3/7 activity was measured using a specific assay that determines cleavage of a luminogenic caspase-3/7
substrate. Data are representative for three independent experiments.
Figure W4. (A) PaTu-8988t cells with Tet-repressible WNT5A expression were incubated in the presence (+) or absence (−) of doxycycline
for 24 hours. WNT5A levels were detected by Western blot; β-actin was used as loading control. (B, C) PaTu-8988t cells (B) and ImimPC1
cells (C) were incubated with rhWNT5A and/or gemcitabine, and apoptosis was measured by PARP cleavage. (D) PaTu-8988t cells with
Tet-repressible WNT5A expression were incubated in the presence (low WNT5A) or absence (high WNT5A) of doxycycline and exposed
to TRAIL for 12 hours. Apoptosis was determined by quantification of histone-bound DNA fragmentation using a specific ELISA. (E) Tumor
growth of subcutaneous ImimPC1 cells stably overexpressingWNT5A or empty control vectors (n= 6 each). Tumor volumewas determined
for 20 days after the tumors had reached a volume of approximately 100 mm3.
Figure W5.WNT5A induces NFATc2mRNA in ImimPC1 cells. (A) ImimPC1 cells were transiently transfectedwithWNT5A siRNA (siWNT5A)
or control siRNA (siC). NFATc2 mRNA was determined by quantitative real-time PCR and normalized to RPLPOmRNA. (B) ImimPC1 cells ±
WNT5A siRNA (siWNT5A) or control siRNA (siC) were cotransfected with a luciferase plasmid containing an NFATc2 promoter fragment.
Promoter activation was measured by luciferase assay. (C) NFATc2 promoter activity was determined after incubation with rhWNTA for
24 hours. *P < .05 as compared with untreated control cells.
Figure W6. WNT5A induces NFATc2 protein in ImimPC1 cells. (A) ImimPC1 cells were transiently transfected with WNT5A siRNA
(siWNT5A) or control siRNA (siC). NFATc2 protein was determined by Western blot; β-actin was used as loading control. (B) ImimPC1 cells
were stably transfected with WNT5A or empty vector (mock), and NFATc2 protein levels were determined by Western blot; β-actin was
used as loading control. (C) Recombinant human WNT5A was added to ImimPC1 cells for various time points, and NFATc2 protein levels
were analyzed by Western blot. (D) WNT5A overexpression in ImimPC1 xenografts is associated with enhanced NFATc2 expression, as
determined by Western blot in the gemcitabine-treated xenograft tissues for which sufficient material for protein lysates was available.
Figure W7.mRNA expression levels of different putativeWNT5A receptors in PaTu-8988t and ImimPC1 cells, as determined by quantitative
real-time PCR after transient transfection with siRNA against WNT5A (siWNT5A) or nonsilencing control (siC). Fzd, Frizzled receptors; Lrp,
low-density lipoprotein receptor–related protein.
Figure W8. WNT5A involves canonical signaling and induces transcriptional activation of NFATc2 in ImimPC1 cells. (A) TOP/FOPflash
indicating canonical Wnt signaling activity ± recombinant human WNT5A (rhWNT5A). (B) ImimPC1 cells were transiently transfected
with WNT5A siRNA (siWNT5A) or control siRNA (siC) and cotransfected with a cisNFAT luciferase plasmid (cisNFATLuc) containing an
NFAT DNA binding motif. NFAT transcriptional activation was measured by luciferase assay. (C) rhWNT5A was added to ImimPC1 cells
after transfection with cisNFAT-Luc. NFAT transcriptional activation was measured by luciferase assay. *P < .05 as compared with
untreated control cells.
Figure W9. (A) NFATc2 knockdown stimulates gemcitabine-induced apoptosis in ImimPC1 cells, as determined by quantification of histone-
bound DNA fragmentation by specific ELISA. (B) NFATc2 knockdown induced by two independent silencing sequences (siNFAT#1 and
siNFAT#2) stimulates gemcitabine-induced apoptosis in PaTu-8988t cells, as determined by quantification of histone-bound DNA frag-
mentation by specific ELISA. (C, D) NFATc2 knockdown stimulates TRAIL-induced apoptosis. ImimPC1 cells were transiently transfected
with NFATc2 siRNA (siNFAT) or control siRNA (siC), and apoptosis was induced with TRAIL for 12 hours. Apoptosis was determined
by quantification of histone-bound DNA fragmentation by specific ELISA (C) and PARP cleavage (D). To control for equal loading, we
reprobed the blots with β-actin antibody.
